Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Capital Expenditures (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Capital Expenditures data on record, last reported at $42000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to $42000.0; the TTM value through Sep 2025 reached $42000.0, down 57.58%, while the annual FY2024 figure was $28000.0, 89.02% down from the prior year.
  • Capital Expenditures reached $42000.0 in Q3 2025 per ASMB's latest filing, up from $14000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.1 million in Q1 2021 and bottomed at $14000.0 in Q1 2024.
  • Average Capital Expenditures over 5 years is $391444.4, with a median of $48000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: skyrocketed 4635.38% in 2021, then tumbled 70.83% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $18000.0 in 2021, then soared by 466.67% to $102000.0 in 2022, then plummeted by 30.39% to $71000.0 in 2023, then plummeted by 80.28% to $14000.0 in 2024, then soared by 200.0% to $42000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $42000.0 in Q3 2025, $14000.0 in Q2 2024, and $14000.0 in Q1 2024.